Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pegcetacoplan (APL-2) for paroxysmal nocturnal haemoglobinuria	Pegcetacoplan (APL-2)	Paroxysmal nocturnal haemoglobinuria (PNH)	Haematology	2019	View \| Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma	FLOT , Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Pembrolizumab in addition to cisplatin and fluorouracil for recurrent locally advanced or metastatic oesophageal cancer – First-line	5-Fluorouracil , Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download
Pembrolizumab in addition to platinum therapy and radiation for unresectable locally advanced head and neck squamous cell carcinoma	Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475)	Head and neck cancer	Head and Neck Cancer	2019	View \| Download
Pembrolizumab in addition to trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – First-line	Pembrolizumab (Keytruda; MK-3475) , Trastuzumab (Herceptin; RG-597)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Pemigatinib for locally advanced or metastatic, relapsed or refractory cholangiocarcinoma with FGFR2 fusion or rearrangement	Pemigatinib (INCB054828)	Cholangiocarcinoma	Gastrointestinal Cancer	2019	View \| Download
Pertuzumab and trastuzumab (fixed-dose combination) in addition to chemotherapy for breast cancer	Pertuzumab and Trastuzumab (Phesgo; RO7198574) (fixed dose combination: Trastuzumab; Pertuzumab)	Breast cancer	Breast Cancer	2019	View \| Download
Pexidartinib for tenosynovial giant cell tumour	Pexidartinib (PLX3397)	Tenosynovial giant cell tumour (TGCT)	Oncology	2019	View \| Download
Pioglitazone for sudden sensorineural hearing loss	Pioglitazone (Actos; AD-4833; pioglitazone hydrochloride)	Sudden sensorineural hearing loss	Ear Nose and Throat (ENT) , Neurology	2019	View \| Download
Ramucirumab in addition to erlotinib for EGFR mutation-positive metastatic non-small-cell lung cancer	Erlotinib (Tarceva; erlotinib hydrochloride) , Ramucirumab (Cyramza)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download